Sandostatin

Type: Product
Name: Sandostatin
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

Glide Pharma completes proof-of-concept study with novel solid dose formulation of octreotide

Glide Pharma, a specialty pharmaceutical development and device company, announced that its novel solid formulation of octreotide acetate achieved successful results in a pre-clinical proof-of-concept study comparing it with the currently marketed liquid ... [Published PharmaBiz - Jul 23 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

Glide Pharma Completes Successful Proof-of-Concept Study with Novel Solid Dose Formulation of Octreotide

OXFORD, EnglandGlide Pharma, the pharmaceutical development and device company focused on solid dose formulations of therapeutics and vaccines, today announced that its novel solid formulation of octreotide acetate achieved successful results in a pre-clinical ... [Published Bio-Medicine - Jul 22 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

The (Only) Eight Mega Cap Dividend Stocks Yielding More Than 3%

With interest rates at an all-time low, high-yield dividend stocks have replaced bonds as the best option to provide a stream of income in a portfolio.Dividend payers deliver the added perk of equity ownership for potential growth. Plus, they tend to ... [Published Money Morning - Jul 18 2014]
First reported Jul 17 2014 - Updated Jul 17 2014 - 1 reports

Novartis Q2 results by key product

07:42 ET | About: Novartis AG (NVS)Novartis (NYSE:NVS) Q2 pharmaceutical sales by selected product: Gleevec/Glivec: $1,199M (+0.8%); Diovan/Co-Diovan: $743M (-19.9%); Gilenya: $606M (+29.5%); Sandostatin: $417M (+3.2%); Exforge: $370M (-1.9%); Afinitor/Votubia: ... [Published Seeking Alpha - Jul 17 2014]
First reported Jul 17 2014 - Updated Jul 17 2014 - 1 reports

Novartis sales boosted by emerging markets and Gilenya

Novartis has posted a solid set financials for the second quarter, with net profit reaching $2.59 billion, up 3%, while group sales edged up 2% to $14.64 billion.Pharmaceutical turnover inched up 1% to $8.20 billion, hit by a 20% fall in sales of the ... [Published Pharma Times - Jul 17 2014]
First reported Jul 16 2014 - Updated Jul 16 2014 - 1 reports

CLARINET Results: Lanreotide First Line for Metastatic NETs

The somatostatin analogue lanreotide ( Somatuline , Ipsen) is significantly better than placebo for controlling progression of many types of metastatic neuroendocrine tumors (NETs), according to the phase 3 CLARINET trial."This double-blind randomized ... [Published General Medicine eJournal - Jul 16 2014]
First reported Jul 14 2014 - Updated Jul 14 2014 - 1 reports

Top 100 Agencies 2014: Biolumina Group

Share this article:Expanding its therapeutic focus helps agency grow its business Biolumina Group has made more headway toward expanding the breadth of therapeutic categories it serves as well as its depth of expertise. Under Ane Jones, president, the ... [Published Medical Marketing And Media - Jul 14 2014]
First reported Jul 14 2014 - Updated Jul 14 2014 - 1 reports

Top 100 Agencies 2014: JUICE Pharma Worldwide

Share this article:Moving past the consolidation hurdle with expansion and strength JUICE Pharma Worldwide's revenue took something of a hit last year, due to the combination of clients in general tightening their budgets and Pfizer's agency consolidation. ... [Published Medical Marketing And Media - Jul 14 2014]
First reported Jul 10 2014 - Updated Jul 10 2014 - 1 reports

Oral Octreotide Could Capture a Share of Injectables Market from Late 2015

Recent trials exhibiting the effectiveness of oral octreotide for treating acromegaly may be a cause of concern for injectable somatostatin analogs (SSAs), providing that the drug's makers find a more convenient medication schedule for patients, says ... [Published PharmaAsia - Jul 10 2014]
Entities: octreotide, Chiasma, Market
First reported Jun 25 2014 - Updated Jun 25 2014 - 1 reports

Let me use cannabis: Gran (Sound Telegraph)

, 11:39 amHayley Goddard A Baldivis grandmother battling cancer wants lawmakers to legalise medicinal marijuana so she can use cannabis instead of prescription medicines.A Baldivis grandmother who has been prescribed a cocktail of pharmaceutical drugs ... [Published Yahoo! News Australia - Jun 25 2014]
First reported May 27 2014 - Updated May 28 2014 - 1 reports

3 Reasons to be Bullish on Teva Pharmaceutical

Source: Thinkstock Teva Pharmaceutical Inudstries Ltd. ( NYSE:TEVA ) has had a bit of a rough year so far: the first quarter of 2014 seems to have been primarily taken up by Teva’s attempts at winning an ongoing battle to delay generic versions ... [Published Wall St. Cheat Sheet - May 27 2014]
First reported May 23 2014 - Updated May 24 2014 - 1 reports

3 Reasons to Be Bullish on Teva

Teva Pharmaceutical Inudstries Ltd.  ( NYSE:TEVA ) has had a bit of a rough year so far: the first quarter of 2014 seems to have been primarily taken up by Teva’s attempts at winning an ongoing battle to delay generic versions of the company’s ... [Published Wall St. Cheat Sheet - May 23 2014]

Quotes

"Own a diversified industrial conglomerate that pays a good dividend; maybe General Electric is a good start," Gilani said earlier this year. "This position plays on the industrial base of machinery, goods, and services that are all necessary for an increasingly industrialized world."
"Based on the CLARINET trial, I think the pattern of practice is changing," Dr. Strosberg concluded. "For many patients, especially those with well-differentiated slow-growing tumors, I think somatostatin analogues are the appropriate first-line choice."
Obamacare Skyrockets Cancer Patient's Meds to $14,000 : "In an emotional Sunday Wall Street Journal editorial, Ralston College President Stephen Blackwood wrote that Obamacare has made his mother's cancer battle a nightmare that will "accelerate her disease and death." He detailed how her Obamacare plan no longer covers the cost of her essential Sandostatin cancer medication, which totaled $14,000 since January 1 alone.Blackwood said his mother, Catherine, had a "terrific" Blue Cross/Blue Shield plan for almost 20 years until Obamacare canceled it. After navigating the "bureaucratic morass" of enrolling in Obamacare, Blackwood says his mother was informed that "the only way to find outout inin detail what was in the plan was to buy the plan."What happened next, writes Blackwood, was shocking. "
...another) surgery, she was informed by Humana that it would not, in fact, cover her Sandostatin, or other cancer-related medications," he explained. "The cost of the Sandostatin alone, since Jan. 1, was $14,000, and the company was refusing to pay."

More Content

All (17) | News (10) | Reports (0) | Blogs (7) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Glide Pharma completes proof-of-concept study w... [Published PharmaBiz - Jul 23 2014]
Glide Pharma Completes Successful Proof-of-Conc... [Published Bio-Medicine - Jul 22 2014]
The (Only) Eight Mega Cap Dividend Stocks Yield... [Published Money Morning - Jul 18 2014]
Novartis Q2 results by key product [Published Seeking Alpha - Jul 17 2014]
Novartis sales boosted by emerging markets and ... [Published Pharma Times - Jul 17 2014]
CLARINET Results: Lanreotide First Line for Met... [Published General Medicine eJournal - Jul 16 2014]
Top 100 Agencies 2014: Biolumina Group [Published Medical Marketing And Media - Jul 14 2014]
Top 100 Agencies 2014: JUICE Pharma Worldwide [Published Medical Marketing And Media - Jul 14 2014]
Oral Octreotide Could Capture a Share of Inject... [Published PharmaAsia - Jul 10 2014]
Let me use cannabis: Gran (Sound Telegraph) [Published Yahoo! News Australia - Jun 25 2014]
3 Reasons to be Bullish on Teva Pharmaceutical [Published Wall St. Cheat Sheet - May 27 2014]
3 Reasons to Be Bullish on Teva [Published Wall St. Cheat Sheet - May 23 2014]
The Blackwood letter [Published Power Line - Apr 03 2014]
A word from Stephen Blackwood [Published Power Line - Mar 08 2014]
Obamacare Skyrockets Cancer Patient's Meds to $... [Published MuskegonPundit - Feb 26 2014]
What would you think if #Obamacare were killing... [Published Sister Toldjah - Feb 24 2014]
Obamacare Skyrockets Cancer Patient's Meds to $... [Published Breitbart Feed - Feb 24 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
3 Reasons to be Bullish on Teva Pharmaceutical [Published Wall St. Cheat Sheet - May 27 2014]
Source: Thinkstock Teva Pharmaceutical Inudstries Ltd. ( NYSE:TEVA ) has had a bit of a rough year so far: the first quarter of 2014 seems to have been primarily taken up by Teva’s attempts at winning an ongoing battle to delay generic versions ...
3 Reasons to Be Bullish on Teva [Published Wall St. Cheat Sheet - May 23 2014]
Teva Pharmaceutical Inudstries Ltd.  ( NYSE:TEVA ) has had a bit of a rough year so far: the first quarter of 2014 seems to have been primarily taken up by Teva’s attempts at winning an ongoing battle to delay generic versions of the company’s ...
The Blackwood letter [Published Power Line - Apr 03 2014]
(Scott Johnson) Catherine Blackwood is counted as a success in the statistics touted by the Obama administration as it continues to peddle Obamacare. She has procured new Obamacare-compliant health insurance. Struggling with carcinoid cancer since 2005, ...
A word from Stephen Blackwood [Published Power Line - Mar 08 2014]
(Scott Johnson) Catherine Blackwood is counted as a success in the statistics touted by the Obama administration as it continues to peddle Obamacare. She has procured new Obamacare-compliant health insurance. Struggling with carcinoid cancer since 2005, ...
Obamacare Skyrockets Cancer Patient's Meds to $... [Published MuskegonPundit - Feb 26 2014]
Obamacare Skyrockets Cancer Patient's Meds to $14,000 : "In an emotional Sunday Wall Street Journal editorial, Ralston College President Stephen Blackwood wrote that Obamacare has made his mother's cancer battle a nightmare that will "accelerate her ...
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.